tert-butyl 3-(2,5-difluorophenyl)piperazine-1-carboxylate | 886768-65-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 3-(2,5-difluorophenyl)piperazine-1-carboxylate
• CAS: 886768-65-6
• 化学式: C₁₅H₂₀F₂N₂O₂
• 分子量: 298.333
• InChiKey: FFGIKYZKXQYOOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-(2,5-difluorophenyl)piperazine-1-carboxylate 、 氯甲酸苄酯 在 三甲胺 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  WO2020115501A5

  摘要：

  公开号：

  WO2020115501A5

文献信息

• [EN] PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)<br/>[FR] COMPOSÉS PHARMACEUTIQUES UTILES EN TANT QU'INHIBITEURS DE LA PROTÉASE SPÉCIFIQUE DE L'UBIQUITINE 19 (USP19)
  申请人：ALMAC DISCOVERY LTD

  公开号：WO2022200523A9

  公开（公告）日：2023-02-16
• PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)
  申请人：ALMAC DISCOVERY LIMITED

  公开号：US20220033397A1

  公开（公告）日：2022-02-03

  Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those a compounds for use in methods of treating muscular atrophy.
• [EN] PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)<br/>[FR] COMPOSÉS PHARMACEUTIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PROTÉASE 19 SPÉCIFIQUE DE L'UBIQUITINE (USP19)
  申请人：ALMAC DISCOVERY LTD

  公开号：WO2020115501A1

  公开（公告）日：2020-06-11

  Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those compounds for use in methods of treating muscular atrophy.